PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11515896-5 2001 RESULTS: Wall motion scores (4, normal, to -1, dyskinesia) were higher in animals treated with ACE inhibitors (3.20+/-0.15 SE enalaprilat versus 3.08+/-0.23 quinaprilat versus 1.52+/-0.07 no ACE; both p < 0.0001 from no ACE). quinaprilat 157-168 angiotensin-converting enzyme Sus scrofa 95-98 11515896-6 2001 Endothelial-dependent relaxation to bradykinin was best preserved in the quinaprilat-treated hearts (32.1%+/-7.6% enalaprilat versus 65.8%+/-12.6% quinaprilat versus 30.6%+/-10.7% no ACE; p < 0.0001 from no ACE; p < 0.005 from enalaprilat). quinaprilat 73-84 angiotensin-converting enzyme Sus scrofa 183-186 11515896-6 2001 Endothelial-dependent relaxation to bradykinin was best preserved in the quinaprilat-treated hearts (32.1%+/-7.6% enalaprilat versus 65.8%+/-12.6% quinaprilat versus 30.6%+/-10.7% no ACE; p < 0.0001 from no ACE; p < 0.005 from enalaprilat). quinaprilat 73-84 angiotensin-converting enzyme Sus scrofa 210-213 11463767-12 2001 In conclusion, Ang-(1-7), like quinaprilat and captopril, potentiates bradykinin by acting as an ACE inhibitor. quinaprilat 31-42 angiotensin-converting enzyme Sus scrofa 97-100